Journey Medical Corp (DERM)vsZoetis Inc (ZTS)
DERM
Journey Medical Corp
$5.12
+3.23%
HEALTHCARE · Cap: $147.33M
ZTS
Zoetis Inc
$78.80
+1.29%
HEALTHCARE · Cap: $32.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 13870% more annual revenue ($9.53B vs $68.18M). ZTS leads profitability with a 27.7% profit margin vs -8.9%. ZTS earns a higher WallStSmart Score of 58/100 (C).
DERM
Avoid28
out of 100
Grade: F
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.8%
Fair Value
$4.97
Current Price
$5.12
$0.15 premium
Margin of Safety
+10.3%
Fair Value
$143.36
Current Price
$78.80
$64.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.3% year-over-year
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 2.5%
Weak financial health signals
Trading at 10.4x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : DERM
The strongest argument for DERM centers on Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : DERM
The primary concerns for DERM are EPS Growth, Market Cap, Operating Margin.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
DERM profiles as a growth stock while ZTS is a declining play — different risk/reward profiles.
DERM carries more volatility with a beta of 1.11 — expect wider price swings.
DERM is growing revenue faster at 23.3% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 28/100), backed by strong 27.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Journey Medical Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?